This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (147)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Oncology  • Oncology, Other  • Gastroenterology  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Scientific Review

Nicholas Shaheen, MD,MPH; David F. Ransohoff, MD

JAMA. 2002;287:1972-1981.

Context  Gastroesophageal reflux disease (GERD) is a risk factor for adenocarcinoma of the esophagus, a rare cancer whose incidence is increasing. Adenocarcinoma may develop from Barrett esophagus, a metaplastic change of the esophageal epithelium from squamous to intestinalized columnar mucosa, which is associated with chronic reflux. Some have recommended that patients with chronic reflux symptoms undergo upper endoscopy to assess for Barrett esophagus and to screen for cancer.

Objectives  To review the evidence linking GERD and Barrett esophagus to esophageal adenocarcinoma and to examine the utility of upper endoscopy as a screening tool in adenocarcinoma of the esophagus among individuals with GERD.

Data Sources  A MEDLINE search was performed to identify all pertinent English-language reports about GERD, adenocarcinoma, and Barrett esophagus from 1968 through 2001. Reports were of randomized controlled clinical trials if available, case-control data if trials were unavailable, and cohort studies if case-control data were unavailable. Pertinent bibliographies were also reviewed to find reports not otherwise identified.

Study Selection and Data Extraction  Studies were selected by using the search terms gastroesophageal reflux, adenocarcinoma, and Barrett's esophagus, with subheadings for classification, complications, drug therapy, economics, epidemiology, mortality, surgery, and prevention and control. Clinical guidelines for the care of subjects with GERD and Barrett esophagus were retrieved and abstracted.

Data Synthesis  Cohort studies demonstrate that symptoms of GERD occur monthly in almost 50% of US adults and weekly in almost 20%. Three large case-control studies demonstrate a positive association between reflux symptoms and risk of adenocarcinoma of the esophagus, with more prolonged and severe symptoms accentuating this risk. However, because of the low incidence of adenocarcinoma of the esophagus and the ubiquity of reflux symptoms, the risk of cancer in any given individual with reflux symptoms is low. No randomized trial data are available to demonstrate either decreased cancer incidence or increased life expectancy in subjects with GERD who undergo screening endoscopy.

Conclusions  Strong evidence supports the association of GERD and adenocarcinoma of the esophagus; however, the risk of cancer in any given individual with GERD is low. Barrett esophagus appears to be a common precursor lesion to this cancer. Given the low absolute risk of cancer in those with GERD and the lack of demonstrated efficacy of endoscopic screening, insufficient evidence exists to endorse routine endoscopic screening of patients with chronic GERD symptoms.

Author Affiliations: Division of Digestive Diseases and Nutrition, Center for Esophageal Diseases and Swallowing, and the Center For Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Clinical Applications
Nicholas Shaheen and David F. Ransohoff
JAMA. 2002;287(15):1982-1986.
ABSTRACT | FULL TEXT  

April 17, 2002
JAMA. 2002;287(15):2009-2010.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Body mass index and Barrett's oesophagus in women
Jacobson et al.
Gut 2009;58:1460-1466.
ABSTRACT | FULL TEXT  

Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk
Cheung et al.
Carcinogenesis 2009;30:1363-1367.
ABSTRACT | FULL TEXT  

Total vs Partial Fundoplication in the Treatment of Gastroesophageal Reflux Disease: A Meta-analysis
Varin et al.
Arch Surg 2009;144:273-278.
ABSTRACT | FULL TEXT  

Gastroesophageal Reflux Disease
Kahrilas
NEJM 2008;359:1700-1707.
FULL TEXT  

Expression Analysis of Barrett's Esophagus-Associated High-Grade Dysplasia in Laser Capture Microdissected Archival Tissue
Sabo et al.
Clin. Cancer Res. 2008;14:6440-6448.
ABSTRACT | FULL TEXT  

Review: Chemoprevention of esophageal adenocarcinoma
Abrams
Therapeutic Advances in Gastroenterology 2008;1:7-18.
ABSTRACT  

A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome
Lanuti et al.
Clin. Cancer Res. 2008;14:3216-3222.
ABSTRACT | FULL TEXT  

MicroRNA expression profiles of esophageal cancer.
Feber et al.
J. Thorac. Cardiovasc. Surg. 2008;135:255-260.
ABSTRACT | FULL TEXT  

The association between gastro-oesophageal reflux disease and asthma: a systematic review
Havemann et al.
Gut 2007;56:1654-1664.
ABSTRACT | FULL TEXT  

Retinoic acid-induced glandular differentiation of the oesophagus
Chang et al.
Gut 2007;56:906-917.
ABSTRACT | FULL TEXT  

BMI and Gastroesophageal Reflux in Women
Kostikas et al.
NEJM 2006;355:848-850.
FULL TEXT  

Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer
Foroulis and Thorpe
Eur. J. Cardiothorac. Surg. 2006;29:30-34.
ABSTRACT | FULL TEXT  

Chronic Cough Due to Gastroesophageal Reflux Disease: ACCP Evidence-Based Clinical Practice Guidelines
Irwin
Chest 2006;129:80S-94S.
ABSTRACT | FULL TEXT  

Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma
Casson et al.
Carcinogenesis 2005;26:1536-1541.
ABSTRACT | FULL TEXT  

Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival?
Dellon and Shaheen
JCO 2005;23:4478-4482.
ABSTRACT | FULL TEXT  

Progression of Barrett's Metaplasia to Adenocarcinoma Is Associated with the Suppression of the Transcriptional Programs of Epidermal Differentiation
Kimchi et al.
Cancer Res. 2005;65:3146-3154.
ABSTRACT | FULL TEXT  

Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma
Helm et al.
Clin. Cancer Res. 2005;11:2478-2485.
ABSTRACT | FULL TEXT  

Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Work-up, and Surgical Approaches
Koshy et al.
The Oncologist 2004;9:137-146.
ABSTRACT | FULL TEXT  

Esophageal Cancer
Enzinger and Mayer
NEJM 2003;349:2241-2252.
FULL TEXT  

Health Care Utilization After Medical and Surgical Therapy for Gastroesophageal Reflux Disease: A Population-Based Study, 1996 to 2000
Khaitan et al.
Arch Surg 2003;138:1356-1361.
ABSTRACT | FULL TEXT  

Acidic pH induces topoisomerase II-mediated DNA damage
Xiao et al.
Proc. Natl. Acad. Sci. USA 2003;100:5205-5210.
ABSTRACT | FULL TEXT  

Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A Cost-Utility Analysis
Inadomi et al.
ANN INTERN MED 2003;138:176-186.
ABSTRACT | FULL TEXT  

A 59-Year-Old Woman With Gastroesophageal Reflux Disease and Barrett Esophagus
Spechler
JAMA 2003;289:466-475.
FULL TEXT  

Endoscopic Screening of GERD Patients: Reviewing the Evidence
JWatch Gastroenterology 2002;2002:4-4.
FULL TEXT